Total Funding
55
55
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
121846
Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
- Monic Stuart: Chief Medical Officer
- John Wilson: CEO & Co-FounderPast Role: Kalaris Therapeutics (formerly AlloVir), Co-Founder and Managing Director
About the Company
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to
kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
